Articles related to Hematology/Oncology

Financial pressures and staffing shortages are creating a challenging environment for oncology care, particularly in community hospitals.

New data suggests that the Galleri blood test’s sensitivity for early-stage cancers may be lower than initially reported, potentially limiting its utility as a screening tool.

The annual cost of cancer screening represents a notable portion of overall U.S. health care system costs related to cancer, with private insurance covering the majority of expenses.

Age bias in oncology can lead to younger patients receiving more aggressive treatments with marginal survival benefits, potentially compromising their quality of life.

Infections account for over 50% of nonrelapse deaths in CAR T-cell therapy patients, outweighing therapy-specific toxicities like ICANS and CRS.

MCED tests aim to detect multiple cancer types through a single blood test, potentially simplifying cancer screening and expanding detection capabilities. However, their implementation raises critical questions about evidence standards and evaluation methods.